Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766191 | 0.81 | P2RX7 (0.71) | GAAP2RX7PLK1LMNAPOLB | |
| SCHEMBL93650 | 0.81 | GAA (0.48) | GAAP2RX7PLK1LMNAPOLB | |
| SCHEMBL165047 | 0.80 | MAPK8 (0.48) | P2RX7LMNAKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL164540 | 0.80 | CHIA (0.56) | P2RX7LMNAKDM4EL3MBTL1KMT2A | |
| SCHEMBL163050 | 0.80 | SMN1; SMN2 (0.58) | GAAP2RX7POLBKDM4EKMT2A | |
| SCHEMBL9569279 | 0.79 | GAA (0.47) | GAAP2RX7PLK1LMNAPOLB | |
| SCHEMBL2306154 | 0.79 | GAA (0.47) | GAAP2RX7PLK1LMNAPOLB | |
| SCHEMBL1467988 | 0.79 | SMN1; SMN2 (0.61) | GAALMNAPOLBTDP1KMT2A | |
| SCHEMBL19983228 | 0.79 | GAA (0.47) | GAAP2RX7PLK1LMNAPOLB | |
| SCHEMBL8173002 | 0.79 | NAPRT (0.61) | GAAP2RX7PLK1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810572-B1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIV BARCELONA (ES) | 2023-11-15 | — | — | EP | claimed |
| CN-112888674-B | Polycyclic compounds as soluble epoxide hydrolase inhibitors | 巴塞罗那大学 | 2023-06-30 | — | — | CN | claimed |
| CN-112888674-A | Polycyclic compounds as soluble epoxide hydrolase inhibitors | 巴塞罗那大学 | 2021-06-01 | — | — | CN | claimed |
| EP-3810572-A1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Universitat de Barcelona (ES) | 2021-04-28 | — | — | EP | claimed |
| WO-2019243414-A1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIVERSITAT DE BARCELONA (ES) | 2019-12-26 | — | — | WO | claimed |
| EP-3810572-B1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIV BARCELONA (ES) | 2023-11-15 | — | — | EP | disclosed |
| CN-112888674-B | Polycyclic compounds as soluble epoxide hydrolase inhibitors | 巴塞罗那大学 | 2023-06-30 | — | — | CN | disclosed |
| CN-112888674-A | Polycyclic compounds as soluble epoxide hydrolase inhibitors | 巴塞罗那大学 | 2021-06-01 | — | — | CN | disclosed |
| EP-3810572-A1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Universitat de Barcelona (ES) | 2021-04-28 | — | — | EP | disclosed |
| WO-2019243414-A1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIVERSITAT DE BARCELONA (ES) | 2019-12-26 | — | — | WO | disclosed |
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | GAA 131/4885P2RX7 1851/4885PLK1 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.